Miltenyi Biotec Gmbh competitive analysis

Explore patent oppositions filed by Miltenyi Biotec Gmbh against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Use Of Chimeric Antigen Receptor-Modified T Cells To Treat CancerTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAJul 2, 2019
Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical ApplicationsGENETHONOct 9, 2018

Explore Miltenyi Biotec Gmbh's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jan 2, 2019Method For Automated Generation Of Genetically Modified T Cells3
Sep 26, 2018Combination Immunotherapy Of Antigen-Recognizing Receptors And Hematopoietic Cells For The Treatment Of Diseases1

Latest PTAB cases involving Miltenyi Biotec Gmbh

Discover the latest PTAB cases involving Miltenyi Biotec Gmbh, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Miltenyi Biotec Gmbh with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MILTENYI BIOTEC GMBH24 - -
D YOUNG29 - - -
GE HEALTHCARE BIO SCIENCES317 - 1
GENETHON - 24 - -